Porzsolt F, Digel W, Jacobsen H, Mittnacht S, Kirchner H, Heimpel H
Department of Medicine III and Tumor Center, University of Ulm, Federal Republic of Germany.
Cancer. 1988 Jan 15;61(2):288-93. doi: 10.1002/1097-0142(19880115)61:2<288::aid-cncr2820610217>3.0.co;2-0.
There is increasing evidence for the therapeutic effectiveness of Interferon-alpha (IFN-alpha) in malignant diseases. However, the antitumor mechanisms of IFN-alpha are not known. Using two examples, hairy Cell leukemia (HCL) and renal cell cancer (RCC), it is shown that the requirements for successful IFN-alpha therapy of HCL and RCC are different. In HCL low doses of IFN-alpha are sufficient to treat the disease. The reduction of hairy cells in peripheral blood is detectable within the first week of treatment. The endogenous IFN-alpha production in these patients is impaired as demonstrated by the lack of IFN-alpha induction and by low levels of 2-5 oligoadenylate synthetase in peripheral blood mononuclear cells. A possible reason for deficient endogenous IFN-alpha production is the lack of monocytes in HCL patients. It is likely that therapy with low doses of IFN-alpha substitutes for the endogenous IFN-alpha deficiency. In RCC comparatively high doses of IFN-alpha are necessary for a clinical response. There may be differences between the effectiveness of natural and recombinant alpha interferons. High doses given within a week seem to be more important than high single doses, which therefore suggests the need of daily treatment. Responses of RCC to IFN-alpha therapy are usually seen several months after the beginning of therapy. These differences in the effectiveness of IFN-alpha therapy for HCL and RCC suggest that IFN-alpha acts differently in the treatment of each disease.
越来越多的证据表明α-干扰素（IFN-α）在恶性疾病治疗中具有疗效。然而，IFN-α的抗肿瘤机制尚不清楚。以毛细胞白血病（HCL）和肾细胞癌（RCC）这两个例子说明，HCL和RCC成功进行IFN-α治疗的要求是不同的。在HCL中，低剂量的IFN-α足以治疗该疾病。治疗第一周内即可检测到外周血中毛细胞减少。这些患者内源性IFN-α产生受损，这可通过缺乏IFN-α诱导以及外周血单个核细胞中2-5寡腺苷酸合成酶水平低得到证明。HCL患者内源性IFN-α产生不足的一个可能原因是缺乏单核细胞。低剂量IFN-α治疗可能替代了内源性IFN-α缺乏。在RCC中，相对高剂量的IFN-α对临床反应是必要的。天然α干扰素和重组α干扰素的有效性可能存在差异。一周内给予高剂量似乎比单次高剂量更重要，因此提示需要每日治疗。RCC对IFN-α治疗的反应通常在治疗开始后几个月出现。IFN-α治疗HCL和RCC有效性的这些差异表明，IFN-α在每种疾病的治疗中作用不同。
